-
公开(公告)号：US20060100211A1
公开(公告)日：2006-05-11
申请号：US11313380
申请日：2005-12-21
申请人： Georg Dahmann , Frank Himmelsbach , Bernd Krist , Martin Lenter , Alexander Pautsch , Gisela Schnapp , Martin Steegmaier , Helmut Wittneben , Anthony Prokopowicz , Walter Spevak , Andreas Schoop , Steffen Steurer
发明人： Georg Dahmann , Frank Himmelsbach , Bernd Krist , Martin Lenter , Alexander Pautsch , Gisela Schnapp , Martin Steegmaier , Helmut Wittneben , Anthony Prokopowicz , Walter Spevak , Andreas Schoop , Steffen Steurer
IPC分类号： C07D403/02 , A61K31/501 , A61K31/506
CPC分类号： C07D239/48 , C07D231/12 , C07D233/56 , C07D239/50 , C07D239/80 , C07D249/08 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/12 , C07D413/12 , C07D413/14 , C07D417/04 , C07D451/04 , C07D451/06 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10
摘要： The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
摘要翻译： 本发明涉及如权利要求1所定义的式（I）的三取代嘧啶，其中R 1和R 2定义如权利要求1所述，其适用于治疗以过量为特征的疾病 或异常细胞增殖，其用于制备具有上述性质的药物组合物的用途及其制备方法。
-
公开(公告)号：US07173028B2
公开(公告)日：2007-02-06
申请号：US10271763
申请日：2002-10-16
申请人： Georg Dahmann , Frank Himmelsbach , Bernd Krist , Martin Lenter , Alexander Pautsch , Gisela Schnapp , Martin Steegmaier , Helmut Wittneben , Anthony S. Prokopowicz , Walter Spevak , Andreas Schoop , Steffen Steurer
发明人： Georg Dahmann , Frank Himmelsbach , Bernd Krist , Martin Lenter , Alexander Pautsch , Gisela Schnapp , Martin Steegmaier , Helmut Wittneben , Anthony S. Prokopowicz , Walter Spevak , Andreas Schoop , Steffen Steurer
IPC分类号： C07D417/10 , C07D239/48 , A61K31/506
CPC分类号： C07D239/48 , C07D231/12 , C07D233/56 , C07D239/50 , C07D239/80 , C07D249/08 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/12 , C07D413/12 , C07D413/14 , C07D417/04 , C07D451/04 , C07D451/06 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10
摘要： The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
摘要翻译： 本发明涉及如权利要求1所定义的式（I）的三取代嘧啶，其中R 1和R 2定义如权利要求1所述，其适用于治疗以过量为特征的疾病 或异常细胞增殖，其用于制备具有上述性质的药物组合物的用途及其制备方法。
-
公开(公告)号：US08420630B2
公开(公告)日：2013-04-16
申请号：US12711364
申请日：2010-02-24
申请人： Georg Dahmann , Frank Himmelsbach , Bernd Krist , Martin Lenter , Alexander Pautsch , Gisela Schnapp , Martin Steegmaier , Helmut Wittneben , Anthony S. Prokopowicz , Walter Spevak , Andreas Schoop , Steffen Steurer
发明人： Georg Dahmann , Frank Himmelsbach , Bernd Krist , Martin Lenter , Alexander Pautsch , Gisela Schnapp , Martin Steegmaier , Helmut Wittneben , Anthony S. Prokopowicz , Walter Spevak , Andreas Schoop , Steffen Steurer
IPC分类号： C07D239/48 , C07D403/12 , C07D401/12 , A61K31/506
CPC分类号： C07D239/48 , C07D231/12 , C07D233/56 , C07D239/50 , C07D239/80 , C07D249/08 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/12 , C07D413/12 , C07D413/14 , C07D417/04 , C07D451/04 , C07D451/06 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10
摘要： The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterized by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
摘要翻译： 本发明涉及式（I）的三取代嘧啶，其中0Ra至Re如权利要求1所定义，其适用于治疗以细胞增殖过度或异常为特征的疾病，其用于制备具有上述药物组合物的用途 性质及其制备方法。
-
公开(公告)号：US07709480B2
公开(公告)日：2010-05-04
申请号：US11313380
申请日：2005-12-21
申请人： Georg Dahmann , Frank Himmelsbach , Bernd Krist , Martin Lenter , Alexander Pautsch , Gisela Schapp , Martin Steegmaier , Helmut Wittneben , Anthony S. Prokopowicz , Walter Spevak , Andreas Schoop , Steffen Steurer
发明人： Georg Dahmann , Frank Himmelsbach , Bernd Krist , Martin Lenter , Alexander Pautsch , Gisela Schapp , Martin Steegmaier , Helmut Wittneben , Anthony S. Prokopowicz , Walter Spevak , Andreas Schoop , Steffen Steurer
IPC分类号： C07D417/00 , C07D239/48 , A61K31/506
CPC分类号： C07D239/48 , C07D231/12 , C07D233/56 , C07D239/50 , C07D239/80 , C07D249/08 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D403/14 , C07D405/12 , C07D413/12 , C07D413/14 , C07D417/04 , C07D451/04 , C07D451/06 , C07D471/04 , C07D471/10 , C07D487/04 , C07D487/10
摘要： The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterized by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.
摘要翻译： 本发明涉及式（I）的三取代嘧啶，其中0Ra至Re如权利要求1所定义，其适用于治疗以细胞增殖过度或异常为特征的疾病，其用于制备具有上述药物组合物的用途 性质及其制备方法。
-
![Pyrido [5, 4-D] pyrimidines as cell proliferation inhibitors](/abs-image/US/2014/02/18/US08653087B2/abs.jpg.150x150.jpg)
公开(公告)号：US08653087B2
公开(公告)日：2014-02-18
申请号：US13062058
申请日：2009-09-08
申请人： Andreas Mantoulidis , Georg Dahmann , Peter Ettmayer , Christian Klein , Steffen Steurer , Irene Waizenegger , Stephan Karl Zahn
发明人： Andreas Mantoulidis , Georg Dahmann , Peter Ettmayer , Christian Klein , Steffen Steurer , Irene Waizenegger , Stephan Karl Zahn
IPC分类号： A01N43/90 , A61K31/519 , C07D487/00
CPC分类号： C07D487/04
摘要： The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, X1, X2, X3, L1 and L2 are defined as in claim 1, which are suitable for the treatment of diseases characterized by excessive or anomalous cell proliferation, and the use thereof in such a treatment.
摘要翻译： 本发明包括通式（1）的化合物，其中R 1至R 4，X 1，X 2，X 3，L 1和L 2基团如权利要求1中所定义，其适用于治疗以过度或异常细胞增殖为特征的疾病， 及其在这种治疗中的用途。
-
![PYRIDO [5, 4-D] PYRIMIDINES AS CELL PROLIFERATION INHIBITORS](/abs-image/US/2012/04/19/US20120094975A1/abs.jpg.150x150.jpg)
6.发明申请公开(公告)号：US20120094975A1
公开(公告)日：2012-04-19
申请号：US13062058
申请日：2009-09-08
申请人： Andreas Mantoulidis , Georg Dahmann , Peter Ettmayer , Christian Klein , Steffen Steurer , Irene Waizenegger , Stephan Karl Zahn
发明人： Andreas Mantoulidis , Georg Dahmann , Peter Ettmayer , Christian Klein , Steffen Steurer , Irene Waizenegger , Stephan Karl Zahn
IPC分类号： A61K31/519 , C07D487/10 , A61K31/55 , A61K31/551 , A61P31/00 , A61K31/541 , A61K31/5377 , A61P35/00 , A61P29/00 , A61P37/00 , C07D487/04 , A61K31/553
CPC分类号： C07D487/04
摘要： The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, X1, X1, X3, L1 and L2 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or anomalous cell pro-liferation, and the use thereof in such a treatment.
摘要翻译： 本发明包括通式（1）的化合物，其中基团R1至R4，X1，X1，X3，L1和L2如权利要求1中所定义，其适用于治疗特征在于过度或异常的细胞因子 并且在这种治疗中使用它们。
-
7.发明授权Pyrimido�5,4!-dipyrimidines, pharmaceuticals containing them, their use and processes for the preparation thereof 失效嘧啶并[5,4] - 二嘧啶，含有它们的药物，其用途和制备方法
公开(公告)号：US5821240A
公开(公告)日：1998-10-13
申请号：US811907
申请日：1997-03-05
IPC分类号： A61K31/00 , A61K31/505 , A61K31/519 , A61K31/529 , A61K31/535 , A61K31/5375 , A61K31/5377 , A61K31/54 , A61K31/541 , A61K31/55 , A61K31/551 , A61P17/00 , A61P17/06 , A61P35/00 , A61P37/00 , A61P43/00 , C07D487/04 , C07D519/00
CPC分类号： C07D487/04
摘要： Pyrimido�5,4-d!pyrimidines of the general formula ##STR1## which have an inhibitory effect on signal transduction mediated by tyrosine kinases, their use for the treatment of disorders, in particular of oncoses, and their preparation. Exemplary compounds are: 4-�(3-Chloro-4-fluorophenyl)amino!-6-�1-methyl-4-piperidinylamino!pyrimido�5,4-d!pyrimidine, and 4-�(3-Chloro-4-fluorophenyl)amino!-6-�trans-4-dimethyl-aminocycohexylamino!pyrimido�5,4-d!pyrimidine.
摘要翻译： 对通过酪氨酸激酶介导的信号转导具有抑制作用的通式为（IMA）的吡啶并[5,4-d]嘧啶，其用于治疗疾病，特别是肿瘤的用途及其制备。 示例性的化合物是：4 - [（3-氯-4-氟苯基）氨基] -6- [1-甲基-4-哌啶基氨基]吡啶并[5,4-d]嘧啶和4 - [（3-氯 - 4-氟苯基）氨基] -6- [反式-4-二甲基 - 氨基胞嘧啶]嘧啶并[5,4-d]嘧啶。
-
8.发明授权7-(piperazine-1-ymethyl)-1H-indole-2-carboxylic acid (phenyl)-amide derivatives and allied compounds as p38 MAP kinase inhibitors for the treatment of respiratory diseases 有权7-（哌嗪-1-基甲基）-1H-吲哚-2-羧酸（苯基） - 酰胺衍生物和相关化合物作为治疗呼吸道疾病的p38 MAP激酶抑制剂公开(公告)号：US08686022B2
公开(公告)日：2014-04-01
申请号：US13060504
申请日：2009-08-26
申请人： Holger Wagner , Birgit Jung , Frank Himmelsbach , Rolf Goeggel , Georg Dahmann
发明人： Holger Wagner , Birgit Jung , Frank Himmelsbach , Rolf Goeggel , Georg Dahmann
IPC分类号： A61K31/40 , A61K31/405
CPC分类号： C07D209/42
摘要： The present invention provides compounds according to general formula (I) which are proposed for the treatment of respiratory complaints, particularly asthma and COPD.
摘要翻译： 本发明提供了用于治疗呼吸道疾病，特别是哮喘和COPD的通式（I）的化合物。
-
9.发明授权Pyrimido�5,4-D!pyrimidines, medicaments comprising these compounds, their use and processes for their preparation 失效嘧啶并[5,4-D]嘧啶，包含这些化合物的药物，其用途和制备方法
公开(公告)号：US5707989A
公开(公告)日：1998-01-13
申请号：US524707
申请日：1995-09-07
IPC分类号： A61K31/505 , A61P7/00 , A61P9/00 , A61P17/06 , A61P29/00 , A61P35/00 , A61P37/00 , C07D487/04 , C07F9/6561 , C07D413/14 , A61K31/535 , A61K31/54 , C07D417/14
CPC分类号： C07D487/04 , C07F9/6561
摘要： The present invention relates to pyrimido�5,4-d!pyrimidines of the general formula ##STR1## in which R.sub.a to R.sub.c are as defined herein, their tautomers, their stereoisomers and their salts, in particular their physiologically tolerated salts with inorganic or organic acids or bases which have valuable pharmacological properties, in particular an inhibiting action on signal transduction mediated by tyrosine kinases, their use for the treatment of diseases, in particular tumor diseases.
摘要翻译： 本发明涉及通式为（I）的其中R a至R c如本文所定义的嘧啶并[5,4-d]嘧啶，其互变异构体，其立体异构体及其盐，特别是其生理上耐受的盐， 具有有价值的药理学特性的无机或有机酸或碱，特别是对由酪氨酸激酶介导的信号转导的抑制作用，其用于治疗疾病，特别是肿瘤疾病的用途。
-
10.发明申请7-(Piperazine-1-Ymethyl)-1H-Indole-2-Carboxylic Acid (Phenyl)-Amide Derivatives and Allied Compounds as P38 Map Kinase Inhibitors for the Treatment of Respiratory Diseases 有权7-（哌嗪-1-甲基）-1H-吲哚-2-羧酸（苯基） - 衍生物和联合化合物作为P38地图用于治疗呼吸系统疾病的激酶抑制剂公开(公告)号：US20110269737A1
公开(公告)日：2011-11-03
申请号：US13060504
申请日：2009-08-26
申请人： Holger Wagner , Birgit Jung , Frank Himmelsbach , Rolf Goeggel , Georg Dahmann
发明人： Holger Wagner , Birgit Jung , Frank Himmelsbach , Rolf Goeggel , Georg Dahmann
IPC分类号： A61K31/397 , C07D403/14 , C07D241/04 , C07D413/14 , A61P11/06 , A61K31/454 , A61K31/55 , A61K31/551 , A61K31/5377 , A61P11/00 , C07D401/14 , A61K31/496
CPC分类号： C07D209/42
摘要： The present invention provides compounds according to general formula (I) which are proposed for the treatment of respiratory complaints, particularly asthma and COPD.
摘要翻译： 本发明提供了用于治疗呼吸道疾病，特别是哮喘和COPD的通式（I）的化合物。
-
-
-
-
-
-
-
-
-
搜索结果
70 条记录 (耗时 0.047 秒)
